Development of a novel biocompatible polymer system for extended drug release in a next‐generation drug‐eluting stent
Source abstract
Abstract
Abstract Drug‐eluting stents have proven superior to bare metal stents with lower restenosis rates. Local delivery of drugs from these stents is achieved in most cases with the help of biostable polymer coatings. However, since the polymer coating remains in the body well after all the drug is released, patients can potentially develop hypersensitivity to these polymers—leading to complications such as late‐stent thrombosis. It is therefore important that the polymers are designed to be biocompatible and well tolerated by the body. The polymer coatings are also expected to be robust and provide good control over elution of the desired drug. This paper describes the development of a unique, proprietary polymer blend system, specially designed to meet these requirements. Mutually compatible, free‐radical‐initiated elastomeric polymers were designed to provide a robust coating and offer a steady, sustained release of the highly hydrophobic drug zotarolimus over an extended period. The polymer blend system is also well tolerated by the hydrophilic environment in vivo, as demonstrated through porcine studies. © 2007 Wiley Periodicals, Inc. J Biomed Mater Res, 2008
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Coronary Interventions and Diagnostics · Antiplatelet Therapy and Cardiovascular Diseases · Cerebrovascular and Carotid Artery Diseases
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (27)
Show source-provided references
1. 10.1016/S0140-6736(03)12275-110.1016/S0140-6736(03)12275-1 ↗
2. 10.1016/S0163-7258(01)00153-X10.1016/S0163-7258(01)00153-X ↗
3. 10.1161/01.CIR.0000019071.72887.BD10.1161/01.CIR.0000019071.72887.BD ↗
4. 10.1016/S0735-1097(99)00486-610.1016/S0735-1097(99)00486-6 ↗
5. 10.1016/S0002-9149(98)00189-110.1016/S0002-9149(98)00189-1 ↗
6. 10.1016/S0002-9343(03)00477-710.1016/S0002-9343(03)00477-7 ↗
7. 10.1016/S0002-9149(98)00191-X10.1016/S0002-9149(98)00191-X ↗
8. 10.1016/j.addr.2006.01.01310.1016/j.addr.2006.01.013 ↗
9. 10.1038/ncpcardio037810.1038/ncpcardio0378 ↗
10. 10.1586/14779072.3.5.95310.1586/14779072.3.5.953 ↗
11. Drug‐eluting stents: Immediate and long‐term results
12. 10.1016/j.jacc.2005.09.04710.1016/j.jacc.2005.09.047 ↗
13. 10.1111/j.1540-8183.2005.00084.x10.1111/j.1540-8183.2005.00084.x ↗
14. Comparison of short‐ and mid‐term outcomes between CYPHER and TAXUS stents in patients with complex lesions of the coronary arteries10.1097/00029330-200601010-00004 ↗
15. 10.1007/s00059-004-2557-510.1007/s00059-004-2557-5 ↗
16. 10.1016/j.jacc.2005.07.07110.1016/j.jacc.2005.07.071 ↗
17. 10.1016/j.amjcard.2005.09.08510.1016/j.amjcard.2005.09.085 ↗
18. 10.1002/ccd.2076910.1002/ccd.20769 ↗
19. 10.1161/CIRCULATIONAHA.104.50893710.1161/CIRCULATIONAHA.104.508937 ↗
20. 10.1056/NEJMoa03507110.1056/NEJMoa035071 ↗
21. 10.1056/NEJMoa03244110.1056/NEJMoa032441 ↗
22. 10.1016/S0140-6736(04)16850-510.1016/S0140-6736(04)16850-5 ↗
23. Randomized, double‐blind, multicenter study of the endeavor zotarolimus‐eluting phosphorylcholine‐encapsulated stent for treatment of native coronary artery lesions: Clinical and angiographic results of the Endeavor II trial
24. CarterAJ HastingE CacerasA JonesR JohnsonM UdipiK OzdilF MelderRJ VirmaniR WilcoxJN.Pharmacokinetics and dose–response effects of a novel slow‐release polymeric zotarolimus eluting stent. In preparation.
25. Udipi K · 2006
26. van Krevlan DW · 1976 · 129
27. Miller M · 1966 · 281